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Akt/mTOR/p70S6K1 signaling pathway plays an important role in the 
pathogenesis of cancer and diabetes. Macrophages and lymphocytes 
are involved in the pathogenesis of diabetes, diabetic atherosclerosis, 
formation of insulin resistance as well as immune response to cancer 
and tumor maintenance. The aim of the study was to determine the Akt 
activation by mTORC2 in peripheral blood mononuclear cell (PBMC) 
of patients with type 2 diabetes and cancer. The following groups were 
studied: control group, patients with type 2 diabetes, cancer patients and 
patients with both cancer and diabetes. The amounts of phospho-Akt (р-
S473) and phospho-p70S6K1 (p-T389) were determined using ELISA 
kits. The amount of phosphorylated Akt significantly increases in PBMC 
of patients with cancer. There was no effect in PBMC from patients with 
type 2 diabetes and significant decrease in the amount of phospho-Akt 
in PBMC of the patients group both with cancer and diabetes. p70S6K1 
activation was observed in PBMC of the groups 2 and 3 patients. Thus, 
chronic diseases such as type 2 diabetes and cancer can affect the sig-
naling mechanisms in blood cells. The state of Akt phosphorylation in 
leukocytes can indicate the activity of mTORC1 and its substrates, which 
may be important for the evaluation of the pathological process and the 
efficacy of the drugs.
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1. Introduction
Protein kinase Akt (v-act murine thymoma viral oncogene homolog) plays a key role in regulation of cell growth, homeostasis, survival, proliferation 
and metabolism [1]. Akt is activated by PDK1 via T308 
phosphorylation in the T-loop of the catalytic domain and 
by rapamycin-insensitive mTORC2 through S473 phos-
phorylation in the hydrophobic region on the C-tail. Akt 
enhances insulin-dependent translocation of GLUT-4 and 
glucose transport, and activates downstream protein ki-
nases mTORC1 and p70S6K that control protein synthesis 
and biogenesis of ribosomes. Dysregulation of the PI3K/
Akt/mTOR/p70S6K signaling lead to severe diseases such 
as cancer, obesity and type 2 diabetes (T2D).
The peripheral blood mononuclear cell (PBMC) in-
clude several types of cells that play a significant role in 
the development of pathological conditions such as diabe-
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tes and cancer [2-4]. The pathway PI3K/Akt is involved in 
the activation of macrophages and lymphocytes, secretion 
of cytokines, initiation of inflammatory processes and im-
mune surveillance failure [5]. 
The serine/threonine kinase mTOR forms two different 
signaling complexes, mTORC1 and mTORC2, by binding 
several proteins. mLST8, DEPTOR, and Tti1/Tel2 com-
plex are contained in both mTORC1 and mTORC2. RAP-
TOR and PRAS40 are specific to mTORC1, and RIC-
TOR, mSin1 and PROCTOR 1/2 are specific to mTORC2. 
These kinase complexes interact with specific substrates 
and initiate various signaling events that modulate cellular 
functions. mTORC1 controls the main cellular anabolic 
processes, linking them to the availability of nutrients; 
mTORC2 phosphorylates and activates Akt, controlling 
cellular metabolism, survival and organization of the cy-
toskeleton. The actions of mTORC1, mTORC2 and Akt 
are closely intertwined in some contexts. Thus, in grow-
ing and proliferating cells, Akt is a critical activator of 
mTORC1, and activated mTORC1 mediates by feedback 
inhibition of mTORC2 and Akt. Therefore, mTORC1, 
mTORC2 and Akt constitute a key metabolic signaling 
network that coordinates many of the metabolic processes 
in growing, proliferating cells and metabolic tissues [6, 7].
The aim of the work was to determine the activation 
of Akt, the main effector kinase of PI3K/Akt/mTORC/
p70S6K cascade, in PBMC of patients with T2D and can-
cer.
2. Materials and methods
The study was conducted in the diabetology department 
of the Institute. All patients signed informed consent to 
conduct further diagnostic and research study. Immediate-
ly after collection, the blood was layered on histopaque 
1077 (Sigma, USA), centrifuged at 500 g (RT) for 15 min 
in the 15 ml conical FalconTM tubes, the PBMC collected 
were washed in PBS and frozen at -80 °C until use. For 
determination of phospho-Akt1/2/3 (р-S473) and phos-
pho-p70S6K1 (p-T389) amounts ELISA kits 85-86046 
and 85-86053 respectively (Invitrogen, USА) were used. 
The studies were carried out in triplets. The cells were 
lysed in the extraction buffer with inhibitors of proteases 
and phosphatases from the kits. The protein concentration 
in the lysate was determined using BCA protein assay 
kit (Novagen, USA). The measurements were carried out 
on a microplate reader (Bio-tek Instruments, USA) at a 
wavelength of 450 nm.
The OD values of samples obtained are located on the 
calibration curve satisfactorily coinciding with a theoreti-
cal line that indicates no scattering of the data.
The results of the study are presented as M ± SD, n = 6 
- 15. To compare the data groups One-Way ANOVA and 
Student’s t-test (with statistical module of Origin 7.0 soft-
ware) were used. Values of P ≤ 0.05 were considered as 
significant. 
The following groups were investigated: 1 – control 
group (n = 6) – healthy people, representative by age; 2 – 
patients with T2D (n = 12); 3 – cancer patients (n = 15); 
4 – patients with both cancer and T2D (n = 7). Patients 
with T2D used combined treatment with insulin and 
metformin. Patients with diabetes (groups 2 and 4) have 
HbA1c level – 7.4-9.2%. Тhe patients of groups 3 and 
4 have uterine, breast and bowel cancers. All examined 
patients belonged to the Caucasian race, age was in range 
from 46 to 72. Gender and BMI characteristics of the pa-
tients are shown in the Table 1. The patients and a control 
group were selected with close age and body mass index.
3. Results and Its Discussion
The PBMC include monocytes/macrophages and lym-
phocytes (T-cell, B-cell, NK) involved in the processes 
of cellular and humoral immunity. PI3K/Akt/mTOR is a 
signaling cascade that largely determines the functioning of 
these blood cells in diabetes and malignant neoplasm [2-4, 8].
As shown in Figure 1“2”, the content of Akt phosphor-
ylated by mTORC2 does not differ from the control in the 
group of patients with diabetes.
Table 1. Gender and BMI characteristics of the patients
І group ІІ group ІІІ group ІV group
Men
(n=3)
Women
(n=3)
Men
(n=6)
Women
(n=6)
Men
(n=5)
Women
(n=10)
Men
(n=3)
Women
(n=4)
Age
(years) 57.0±1.70 60.0±3.71 60.17±2.94 57.50±1.17 60.4±5.8 59.2±2.19 61.3±2.12 55.5±1.9
BMI
(кg/m2) 27.39±2.37 30.22±1.13 32.44±1.25 32.12±1.49 30.75±1.46 32.47±0.93 32.8±1.6 29.2±1.8
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Figure1. Amount of phospho-Akt1/2/3 (р-S473) in pe-
ripheral blood mononuclear cell of patients with cancer 
and diabetes
PBMC cells were isolated from the blood, lysed in the 
extraction buffer with inhibitors of proteases and phos-
phatases and phospho-Akt1/2/3 amounts was determined 
using of ELISA kits.
All patients belonged to the Caucasian race with age 
in range from 46 to 72. The patients and a control group 
were selected with close age and body mass index.
1 - control (n = 6); 2 - patients with type 2 diabetes (n = 
12); 3 - cancer patients (n = 15); 4 patients with both dia-
betes and cancer (n = 7). To compare the data groups One-
Way ANOVA and Student’s t-test were used. M ± SD, * 
- the difference from the control group is significant, P 
<0,05.
It is known that in tissues of patients with T2D, as a 
result of prolonged exposure to high doses of insulin, the 
activity of Akt and its downstream kinases, mTORC1 
and p70S6K, is enhanced, resulting in phosphorylation 
of key adapter protein IRS-1 (S307 and other amino acid 
residues), its degradation, impaired insulin signaling and, 
consequently, insulin resistance [9]. The level of phosphor-
ylated Akt in PBMC of patients with T2D is probably 
determined by the ratio of metformin and insulin effects. 
Metformin activates the AMPK and inhibits mTORC1 
activity, but improves insulin signaling. Insulin activates 
the signaling cascade of PI3K/Akt/mTORC1 and inhibits 
the activation of AMPK by metformin [10]. The final result 
of the interaction of these drugs and the signaling mecha-
nisms induced is the state of Akt activity.
At the same time, in PBMC of patients with T2D we 
observed 143.4±18.9% (M±SD) enhancement of p70S6K1 
phosphorylation (p-T389), indicating the activity of 
the PI3K/Akt/mTORC1/p70S6K1 pathway. Obviously, 
mTORC2 does not participate in the activation of Akt in 
this context.
It has been shown earlier that PBMC of patients with 
systemic insulin resistance express matrix metallopro-
teinase 9, hypoxia-induced factor 1α, split AMPKα, IRS-
1 phosphorylated on S312, Akt phosphorylated on T308, 
and TLR4 [11, 12]. TLR4 activation in macrophages caused 
increased expression of scavenger receptors via mTORC2/
Akt/mTORC1 signaling cascade which accelerates oxLDL 
uptake and foam cell formation – key event in the patho-
genesis of atherosclerosis [13].
In PBMC of cancer patients enhancement of Akt phos-
phorylation (p-S473) was observed (Figure 1.3). The 
phosphorylation level of p70S6K is also increased to 
120.6±9.17 %. Thus, mTORC2 may contribute in activa-
tion of mTORC1 and its downstream targets.
It is well established that the PI3K/Akt pathway is fre-
quently dysregulated in cancer [14]. Unlike mTORC1, the 
regulation of mTORC2 and its functional contribution to 
cancerogenesis remain poorly understood. Recent studies 
demonstrate that an intact mTORC2 is required for the ac-
tivation of Akt in vitro and in vivo [15]. mTORC2 combines 
the effects of extracellular growth factors and survival sig-
nals with pathways controlling cell growth and prolifera-
tion. mTORC2 binds extracellular signals (such as growth 
and cytokine factors) with mTORC1 activation, cell 
proliferation and survival through direct phosphorylation 
of the protein kinase Akt on Ser473 in its hydrophobic 
C-tail that is required for its maximum activation [16]. Both 
complexes control each other, since the Akt regulates the 
phosphorylation of PRAS40, which disinhibits the activity 
of mTORC1, while p70S6K regulates Sin1 to modulate 
the activity of mTORC2 [17].
It has been shown that loss of mTORC2 in macro-
phages suppresses tumor growth. The mTORC2-mediated 
pathway comprising PI3K and Akt, is important for the 
accented glucose metabolism, promotes the activation of 
M2 macrophages (alternatively activated macrophages) 
and involves M-CSF as an upstream activator. M2 macro-
phages function in constructive processes, such as wound 
healing and tissue repair, and disable the activation of the 
damaging immune system by the secretion of anti-inflam-
matory cytokines such as IL-10 [18]. It is also known that 
macrophage M2 polarization – a key pro-tumoral phe-
nomenon [19]. mTORC2 activity was found to be elevated 
in glioma cell lines and primary tumors as compared with 
normal brain tissue. Xenograft studies also supported a 
role for increased mTORC2 activity in tumorigenesis and 
enhanced tumor growth [20].
There was estimated a strong link between diabetes (es-
pecially T2D) and cancer. Hyperinsulinemia enhances the 
expression of insulin and IGF receptors that causes a cu-
mulative mitogenic effect. Hyperglycemia provides can-
cer cells with excess of glucose [21]. Therefore somewhat 
DOI: https://doi.org/10.30564/jer.v1i1.674 
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unexpected was the decrease in the amount of phospho-
Akt (Figure1“4”) in the PBMC of patients group both 
with cancer and diabetes. The level of phosphorylation 
of p70S6K is also reduced to 89.7 ± 6.27% of the control 
level and more than 30% compared to the cancer group 
(Figure 1“3”). Consequently, in the PBMC of group 4 
patients the activity of Akt, mTORC1 and p70S6K is sig-
nificantly suppressed, as compared to the group of cancer 
patients. 
Probable explanation for such inhibition may be 
competition for common signaling mechanisms. It is 
also possible the participation of tumor suppressors, such 
as TRIB3 (Tribbles pseudokinase 3), which suppress 
activation of Akt by mTORC2 in tumors [22]. The involve-
ment of IKKα, a subunit of the IKK complex that controls 
NF-κB activation, is also not excluded. IKKα regulates 
the mTORC2 kinase activity directed to Akt on S473 and 
Akt-mediated phosphorylation of FOXO3a and GSK-
3β, but not other Akt-associated targets such as TSC2 and 
PRAS40, which control the mTORC1/p70S6K activity [23]. 
TLR4 expression in macrophages mentioned above could 
activate NF-κB signaling [24].
It should be noted that we did not observe a significant 
difference in the activity of both kinases in the PBMC be-
tween patients with different types of cancer within groups 
3 and 4. We also did not observe gender differences.
4. Conclusion
Thus, chronic diseases such as type 2 diabetes and cancer 
may have a systemic effect on signaling mechanisms in 
different tissues of the body, including blood cells. The 
state of Akt phosphorylation in PBMC can indicate the 
activity of mTORC1 and its substrates, which may be im-
portant for the evaluation of the pathological process and 
the efficacy of the drugs.
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